Pre ‐anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Publication date: Available online 19 October 2018Source: Pharmacology &TherapeuticsAuthor(s): Ryuji Yamaguchi, Lydia Lartigue, Guy PerkinsAbstractRegulation of both the extrinsic and the mitochondria-dependent intrinsic apoptotic pathways plays a key role in the development of the hematopoietic system, for sustaining cell survival during generation of various cell types, in eliminating cells with dual identities such as CD4/CD8 double-positive cells1,2, for sustaining cells during the rapid clonal expansion phase3, as well as eliminating cells during the contraction phase4. The anti-apoptotic protein Mcl-1 is necessar...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 October 2018Source: Pharmacology &TherapeuticsAuthor(s): Joseph T. Madak, Armand Bankhead, Christine R. Cuthbertson, Hollis D. Showalter, Nouri NeamatiAbstractIdentified as a hallmark of cancer, metabolic reprogramming allows cancer cells to rapidly proliferate, resist chemotherapies, invade, metastasize, and survive a nutrient-deprived microenvironment. Rapidly growing cells depend on sufficient concentrations of nucleotides to sustain proliferation. One enzyme essential for the de novo biosynthesis of pyrimidine-based nucleotides is dihydroorotate dehydrogenase (DHODH), a known t...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 6 October 2018Source: Cancer GeneticsAuthor(s): Xinjie Xu, Christine Bryke, Madina Sukhanova, Emma Huxley, D.P. Dash, Amanda Dixon-Mciver, Min Fang, Patricia T. Griepp, Jennelle C. Hodge, Anwar Iqbal, Sally Jeffries, Rashmi Kanagal-Shamanna, Fabiola Quintero-Rivera, Shashi Shetty, Marilyn L. Slovak, Ashwini Yenamandra, Patrick A. Lennon, Gordana RacaAbstractStructural genomic abnormalities, including balanced chromosomal rearrangements, copy number gains and losses and copy-neutral loss-of-heterozygosity (CN-LOH) represent an important category of diagnostic, prognostic and therapeutic ma...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Authors: Duployez N, Preudhomme C, Cheok M PMID: 30338031 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by the abnormal proliferation and differentiation of hematopoietic stem cells. Patients diagnosed with AML often have a poor prognosis, with long term survival being affected by subtype of disease, therapy given, and ability to tolerate treatment [1]. An important classifier of the disease that can predict response to therapy and outcome is the presence of recurrent cytogenetic abnormalities. Patients with recurrent 3q mutations such as inv(3)(q21q26.2) or t(3;3)(q21;q26.2) represent a subgroup of AML with a very poor prognosis due to the high rates of ...
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
The presence of recurrent genetic mutations in the myeloblasts of patients with acute myeloid leukemia (AML) are prognostic and incorporated into risk stratification systems of both the National Comprehensive Cancer Network and European Leukemia Network.1 In patients with FLT3-internal tandem duplications (FLT3-ITD) or tyrosine kinase domain mutations (TKD) small molecule inhibitors of the resultant mutant proteins in combination with cytotoxic chemotherapy can improve overall survival in newly diagnosed AML patients with a FLT3 mutation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Acute myeloid leukemia (AML) represents a malignant clonal expansion of myeloid progenitor cells in the peripheral blood and bone marrow. Overall, the prognosis in AML is suboptimal, with less than 30% of AML patients achieving a long-term remission. When factoring age, as older patients are not often offered intensive therapy, survival in this group is even more morbid, and is often measured only in months. [1] Recently, through advancements in cytogenetic and next generation techniques, there has been a substantial improvement in the understanding of the wide genomic landscape in AML.
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
Conclusion: A combined diagnostic approach including biochemical, microbiological and pathological evaluation was useful in eliminating infectious meningitis and confirming neoplastic meningitis in these cases. Cytology should be performed on cerebrospinal specimens from all patients with known or suspected malignancy with meningismus. Detection of malignant cells on cytological examination of CSF is the diagnostic gold standard for neoplastic meningitis.
Source: Journal of Cytology - Category: Cytology Authors: Source Type: research
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study, Published online: 19 October 2018; doi:10.1038/s41409-018-0356-5Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia